Basal insulin analogues (MedImmune)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBasal insulin analogues (MedImmune)
Drug Alias NameInsulin-Fc variants
ClassificationBiologics
Mechanisms of ActionPhosphokinases stimulantsProtein-tyrosine kinases inhibitorsOrnithine decarboxylase stimulants
TargetsPhosphokinasesProtein-tyrosine kinasesOrnithine decarboxylase
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesMedimmune Llc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A